🚀 VC round data is live in beta, check it out!
Mabion Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mabion and similar public comparables like Prescient Therapeutics, INmune Bio, Passage Bio, Imugene and more.
Mabion Overview
About Mabion
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
Founded
2007
HQ
Employees
204
Website
Financials (FY)
EV
$38M
Mabion Financials
Mabion reported last fiscal year revenue of $19M and EBITDA of $3M.
In the same fiscal year, Mabion generated $11M in gross profit, $3M in EBITDA, and had net loss of ($2M).
Mabion P&L
In the most recent fiscal year, Mabion reported revenue of $19M and EBITDA of $3M.
Mabion expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $19M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $11M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 60% | XXX | XXX | XXX |
| EBITDA | — | XXX | $3M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (2%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (9%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mabion Stock Performance
Mabion has current market cap of $38M, and enterprise value of $38M.
Market Cap Evolution
Mabion's stock price is $2.35.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $38M | $38M | -0.5% | XXX | XXX | XXX | $-0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMabion Valuation Multiples
Mabion trades at 2.0x EV/Revenue multiple, and 13.3x EV/EBITDA.
Mabion Financial Valuation Multiples
As of April 18, 2026, Mabion has market cap of $38M and EV of $38M.
Equity research analysts estimate Mabion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mabion has a P/E ratio of (21.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $38M | XXX | $38M | XXX | XXX | XXX |
| EV (current) | $38M | XXX | $38M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 13.3x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (119.2x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.3x | XXX | XXX | XXX |
| P/E | — | XXX | (21.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 4.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mabion Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mabion Margins & Growth Rates
Mabion's revenue in the last fiscal year declined by (54%).
Mabion's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Mabion Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (54%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (83%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 60% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 61% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mabion Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mabion | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| INmune Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Passage Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Sprint Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mabion M&A Activity
Mabion acquired XXX companies to date.
Last acquisition by Mabion was on XXXXXXXX, XXXXX. Mabion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mabion
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMabion Investment Activity
Mabion invested in XXX companies to date.
Mabion made its latest investment on XXXXXXXX, XXXXX. Mabion invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mabion
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mabion
| When was Mabion founded? | Mabion was founded in 2007. |
| Where is Mabion headquartered? | Mabion is headquartered in Poland. |
| How many employees does Mabion have? | As of today, Mabion has over 204 employees. |
| Is Mabion publicly listed? | Yes, Mabion is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Mabion? | Mabion trades under MAB ticker. |
| When did Mabion go public? | Mabion went public in 2010. |
| Who are competitors of Mabion? | Mabion main competitors are Prescient Therapeutics, INmune Bio, Passage Bio, Imugene. |
| What is the current market cap of Mabion? | Mabion's current market cap is $38M. |
| What is the current revenue of Mabion? | Mabion's last fiscal year revenue is $19M. |
| What is the current EV/Revenue multiple of Mabion? | Current revenue multiple of Mabion is 2.0x. |
| Is Mabion profitable? | No, Mabion is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.